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ABSTRACT 
Redox homeostasis is the balance between cellular prooxidants and antioxidants, maintained 
by the interplay of electrons. Reactive oxygen species (ROS) is a term for molecules with 
unpaired valence electrons or unstable bonds. Initially thought to predominantly produce 
cellular damage, ROS were found to be key mediators in several biological processes. These 
events are primarily facilitated by modulating free thiol groups. However, an imbalance due 
to an excessive generation of ROS or a dysfunction of the cellular antioxidant response leads 
to oxidative stress. Prolonged exposure to oxidative stress is implicated in several disorders, 
including ischemia and reperfusion injury, neurodegenerative disorders, cardiovascular 
disease, and cancer. Cancer cells in particular acquire an increased basal level of ROS, 
attributed to high cellular metabolism, which renders the cells vulnerable to subtle changes in 
redox levels. This can be harnessed in cancer therapy by inducing ROS-generation, pushing 
the level of oxidative stress beyond the tolerance of the cell. Several cytostatic agents used in 
the clinic today use this approach to target malignant cells. Inherent and acquired resistance is 
however a problem as many chemotherapeutic drugs exhibit single-target sites. Resistance is 
elicited by target site modifications, multidrug resistant efflux pumps, or upregulation of 
redox proteins and detoxification pathways.  
I. Expression patterns of redox proteins in cells and tissue with oxidative stress 
Upregulation of thioredoxin (TXN) and glutaredoxin (GLRX) proteins is an event seen in 
many tumor cells. Investigation of the expression pattern of these oxidoreductases was 
conducted in hepatocellular carcinoma patients in Paper I. TXN1 and TXN2, and GLRX5 
were found to be upregulated compared to the surrounding liver tissue. In colorectal liver 
metastases tissue, TXN1 and TXN2, GLRX1, GLRX3 and GLRX5 were upregulated. These 
results might merit the implementation of oxidoreductases as diagnostic markers for 
hepatocellular carcinoma (HCC).  
Portal triad clamping was used in Paper II as a controlled experimental setting for 
investigating alterations in TXN and GLRX upon induced oxidative stress by ischemia and 
reperfusion. Ultrastructural changes revealed that ischemic mediated damage was borne by 
the liver sinusoidal endothelial cells (LSECs). At reperfusion the LSECs re-attached to some 
extent with signs of activation. No differences in redox protein expression could be found 
between the different states of oxygen tension in the tissue. This indicated that the prompted 
oxidative stress in the tissue by short periods of ischemia and reperfusion probably result in 
reversible modifications in the tissue.  
II. Induction of oxidative stress via ROS generation by redox active selenium compounds  
Redox active selenium compounds are promising candidates for the application in cancer 
therapy. Selenite and methylselenocysteine are two compounds with the highest therapeutic 
potential. Their tumoricidal effects are facilitated by their reactive metabolites. In Paper III, 
Modulation of the MSC metabolizing enzyme kynurenine aminotransferase (KYAT) was 
implemented in order to increase the growth inhibitory effects of the selenium compound. 
KYATs are PLP-dependent cysteine S-conjugate β-lyases, that display both transaminase and 
β-lyase activity. Overexpression of KYAT1 resulted in increased sensitivity towards MSC. 
Further modulation of the enzyme by site directed mutagenesis in the active site allowed for a 
phenotype that favors β-elimination over transamination. This was done in order to increase 
the cleavage of MSC to the reactive methylselenol. Mutant KYAT1 further sensitized the 
cells towards MSC to an exceptional level.  
Growth inhibitory effects of selenide, MSC and two novel selenium compounds, Seleno-
folate and Seleno-aniline were compared between cells grown in 2D and cells grown in 3D 
spheroids in Paper IV. Increased resistance towards selenite and Seleno-aniline was seen in 
the 3D culture. Additionally, the use of an ex vivo organotypic model was used as a novel 
drug screening system. The culture consisted of surgical specimens of pancreatic 
adenocarcinoma (PDAC) grown on an insert in wells. Our results revealed that MSC could 
lower the metabolic activity of the tissue components as well as reduce the number of cells 
associated with tumorous outgrowth in the cultured section. 
Taking the results in part II together, MSC is found to be highly interesting for 
chemotherapeutic purposes, both as a single agent and in combination with conventional 
cytostatic drugs. Increasing the sensitivity towards MSC by modulating its metabolizing 
enzyme could serve to develop an increased specificity towards the compound.  
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Comment on terminology 
Problematics arise in scientific literature with the ambiguity regarding gene and protein 
names. Important reports are overlooked and confusion befalls due to the use of synonyms or 
subjective abbreviations.  
In an ideal world gene and protein names would be the same and applicable for all 
orthologues. A recommendation exists, to use the designated and approved gene name in 
italics, XXX and the same name for the protein XXX (not italicized). For mouse; Xxx for 
genes and XXX for proteins. The approved names are retrieved from the Hugo Gene 
Nomenclature Committee (HGNC). 
This is implemented throughout the introductory chapters of this thesis. However, the 
published manuscripts do not conform to this as the previously accepted and most common 
abbreviations were used. In detail, this will mainly entail the abbreviations used for 
thioredoxin and glutaredoxin which are referred to as Trx and Grx respectively in the 
published manuscripts. Given that the gene names are TXN and GLRX, the proteins are 
abbreviated TXN and GLRX throughout the introductory chapter.  
Exception to this rule was applied when referring to the protein kinases involved in the 
mitogen activated protein kinase family (MAPK). The traditional nomenclature was used for 
easier differentiation between the pathway routes.  
Traditional name Approved name according to HGNC  
ERK1 MAPK3 
ERK2 MAPK1 
ERK3 MAPK6 
JNK1 MAPK8 
JNK2 MAPK9 
JNK3 MAPK10 
p38α MAPK14 
p38β MAPK11 
p38γ MAPK13 
p38δ MAP12 
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1 BACKGROUND 
1.1 OXIDATIVE STRESS 
The original definition of oxidative stress in redox biology was proposed in 1985 [1]; 
“A disturbance in the prooxidant-antioxidant balance in favor of the former” 
With emerging evidence of the role of ROS in signaling pathways, the definition was later 
updated [2, 3]; 
“An imbalance between oxidants and antioxidants in favor of the oxidants, leading 
to a disruption of redox signaling and control and/or molecular damage” 
In terms of homeostasis, confusion might arise in relation to the two factors involved in its 
regulation, prooxidants and antioxidants. Early reports worked with a more literal 
interpretation of the balance between oxidants and their reductants. However, the concept of 
redox balance does not implicit a benefit of supplementation of a vitamin with potential 
antioxidant properties to combat a prooxidant milieu. There are several factors to be taken 
into consideration. Endogenous antioxidant defense exhibits specificity towards substrates, 
extracellular compartmentalization, feedback regulatory mechanisms, and can depend on 
extent of oxidative burden.  
An additional level of complexity arises as the previous notion of ‘bad oxidants and good 
antioxidants’ is being reappraised. In chemistry, an antioxidant is a nucleophilic reductant 
capable of reacting with an electrophilic oxidant. An electrophile receives electrons from a 
molecule donating electrons, nucleophile [4]. Electron transfer can involve a one- or a two-
electron reaction by a hydrogen atom (H•) or a hydride (H) respectively.  
A novel term ascribing a cells adaptive response to increased oxidants is ‘Nucleophilic Tone’ 
[5, 6]. It relates to the cellular capacity to remove oxidants, in this form termed electrophiles, 
by the use of enzymes that are nucleophilic substrates. This is explained to be the biologically 
relevant antioxidant defense systems primarily maintained by nicotinamide adenine 
dinucleotide phosphate (NADPH), produced from glucose oxidation in the pentose shunt 
pathway. In this setting, the biologically relevant antioxidant defense is enzyme catalyzed 
reactions as opposed to free radical scavenging by non-enzymatic means. The authors 
describe the effects seen in vitro by ROS scavengers to merely be sensitivity towards 
oxidation. This would explain the limited effects exhibited in vivo by ‘antioxidant 
scavengers’. A discussion of the accuracy and relevance of such a term as opposed to the 
traditional view, reach beyond the scope of this thesis, however it is lifted as an historical 
development within the field of redox biology.   
  
 2 
2 REACTIVE OXYGEN SPECIES 
Reactive oxygen species (ROS) is a collective term for molecules holding unpaired valence 
electrons or unstable bonds. This comes to include radical as well as non-radical agents. 
Within the group of radical molecules of ROS are for instance the superoxide anion (i 
hydroxyl radical (•OH), and nitric oxide (NO). Non-radical species include hydrogen 
peroxide (H2O2), singlet oxygen (
1O2), and hypochlorous acid (HOCl).  
2.1 FREE RADICALS AND THEIR DERIVATIVES 
A leakage of electrons occurs as cellular respiration proceeds in the mitochondria through 
oxidative phosphorylation. Intracellular sources of ROS primarily arise from an initial one 
electron transfer to O2 resulting in the formation of O2
•. The anion is short-lived and non-
permeable to cellular membranes. Rapidly, it is converted to H2O2 spontaneously or through 
reduction by superoxide dismutase (SOD) [7, 8]. The H2O2 has a longer half-life and 
membrane permeable, eliciting many of the ROS-mediated effects in the cell [9] (section 
2.2). A highly reactive •OH can be formed from H2O2 through a Fenton reaction catalyzed by 
iron [10].  An additional path leading to the formation of •OH is via an iron catalyzed Haber-
Weiss reaction from O2
• [11, 12]. H2O2 is oxidized for clearance by catalase [13], 
glutathione (GSH), glutathione peroxidase (GPX) [14], peroxiredoxins (PRDX) [15]. 
However, myeloperoxidases are able to transform H2O2 to HOCl, with subsequent formation 
of a 1O2 [16].  The biological molecule NO is regulated by nitric oxide synthetases (NOS) and 
has little reactivity with other molecules. Cells harbor inducible, neuronal, and endothelial 
NOS (iNOS, nNOS, and eNOS respectively) depending on the tissue origin and cellular type 
[17]. Upon reaction between NO and O2
• the highly reactive peroxynitrite (ONOO) is 
formed [18] (Figure 1). 
2.2 ROS IN PHYSIOLOGY 
The high reactivity of ROS gave rise to the understanding that they produce cellular damage 
and by 1956 the role of ROS in the aging process was established [19]. Several external 
stimuli resulting in ROS-mediated damage were found throughout the years, including 
exposure to tobacco smoke [20, 21], ionizing radiation [22], ultraviolet light [23], and certain 
allergens and pollutants [24, 25].  A beneficial aspect of these agents was found when their 
presence were implicated in host defense. Phagocytes were found to produce O2
• which 
subsequently formed H2O2 in order to kill pathogens [26, 27].  
The notion that ROS exclusively elicits impairments reformed when it was first 
acknowledged that NO participated in vascular homeostasis [28, 29]. Further findings 
entailed that they also serve as signaling molecules and take part in essential normal 
physiological processes [17, 30, 31]. 
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2.2.1 Endogenous sources  
A primary source for ROS-production is mitochondrial leakage of electrons from oxidative 
phosphorylation. The electrons are involved in the generation of O2
• (Figure 1).  Other 
sources are metabolic processes giving rise to ROS as byproducts or ROS generation by 
NAPDH oxidase (NOX). The NOX family of enzymes are transmembrane proteins with the 
specific functionality to produce ROS in order to facilitate electron entry into the cell [17, 
30]. They were first found to be responsible for immune cells capability of producing ROS 
[32]. However, this activity is not limited to phagocytes as additional isoforms were 
discovered in various tissues [17]. To date, the only function known of this family of 
enzymes is the production of ROS.  
Figure 1, ROS chemistry. In the presence of electrons, O2 forms the free radical O2•-. The anion dismutase 
spontaneously to H2O2 or by SOD. Clearance occurs via oxidation mainly by catalase, GSH, GPX or PRDX. 
H2O2 can form other ROS species by an iron catalyzed Fenton reaction giving rise to •OH which can also be 
formed directly from O2• by a Haber-Weiss reaction. The other type of species arising from H2O2 is HOCl in 
the presence of peroxidases which subsequently forms 1O2. NO is produced by eNOS, iNOS or nNOS and the 
molecule reacts with O2• resulting in the formation of the highly reactive ONOO. O2•, superoxide anion; 
H2O2, hydrogen peroxide; SOD, Superoxide dismutase; GSH, glutathione; GPX, glutaperoxins; PRDX, 
peroxiredoxins; •OH, hydroxyl radical; HOCl, hydrochlorous acid; 1O2, singlet oxygen; NO, nitric oxide; 
eNOS, endothelial nitric oxide synthetase; iNOS, inducible nitric oxide synthetase; nNOS, neuronal nitric 
oxide synthetase; ONOO, peroxynitrite. 
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The amino acid cysteine is characterized by high nucleophilicity and sensitivity towards 
oxidative modifications. The thiol of the free amino acid holds a pKa of 8 or 9, however, it 
can be as low as 3 or 4 in certain proteins due to the surrounding residues present in the 
protein. Recent advances in large scale proteomics identified over 500 proteins with reactive 
cysteine residues [33]. These redox state-responsive proteins implicate ROS in several 
cellular functions. 
2.2.2 Post-translational modifications  
Different cysteine residues within the same protein exhibit different reactivity towards 
oxidation. The highly reactive thiol groups (–SH) on these amino acids are primarily situated 
in the regulatory parts of a protein while the less reactive reside in the active site [33, 34]. 
This allows for post-translational modifications in the form of ROS-mediated oxidation, 
nitration and hydroxylation [30, 31, 35, 36] (Figure 2). Alterations to the –SH group include 
nitrosylation upon reaction with NO or nitrothiols from ONOO. The thiol group can also be 
oxidized to sulfenic acid, in a reversible process, by H2O2. Sulfenic acid serves as a reactive 
transient state with important roles in signaling pathways and in defense against oxidative 
stress [37]. Non-enzymatic protein folding by cysteine thiol modification is mediated through 
sulfenic acid as well [38]. Additional redox regulation of the –SH and sulfenic acid include 
the formation of disulfide bonds and glutathionylated proteins. These are processes mediated 
by the thioredoxin superfamily family of proteins and the GSH/GSSG (section 3.1). 
Excessive ROS can lead to higher oxidation states of cysteine, forming sulfinic and sulfonic 
acid. As the oxidation increases, the nucleophilicity decreases due to greater positive charge 
on sulfur. All of the above modifications can modulate the conformation, stability, activity or 
the function of a protein [38-40]. 
2.2.3 Intracellular signaling 
Redox signaling is a term describing a signal delivered to a regulatory process by redox 
chemistry [35]. Target proteins are transiently oxidized for transmission of a signal within a 
pathway. Subsequent reduction occurs to inactivate the target protein and attenuate the signal 
[41]. This mechanism allows for activation of specific pathways by the thiol proteins 
sensitivity to oxidation. Thus, different signaling cascades proceed depending on the level of 
physiological oxidative stress. 
Reports found that O2
• and its derivatives H2O2 and 
•OH could activate guanylate cyclase 
leading to the formation of cGMP [42, 43]. Target proteins are being directly oxidized by 
ROS as opposed to as a consequence of an imbalance in the redox homeostasis. This is 
evident as H2O2 activates Antioxidant Response Element (ARE) by mitogen active protein 
kinase (MAPK) pathways without alterations in the cellular glutathione status [44].  
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The activation of transcription factor NFKB [45] and nuclear factor (erythroid-derived 2)-like 
2 (NFE2L2) occurs by H2O2 in an indirect manner. Oxidation rather takes place on their 
respective regulatory inhibtors, IKB [46, 47] and kelch like ECH associated protein 1 
(KEAP1) [48]. The regulation is mediated by specific reactive cysteine residues in the 
KEAP1 protein [49]. Translocation of the transcription factors to the nucleus occurs as the 
inhibitors dissociate in response to ROS. Additional ROS-mediated modifications includes 
epigenetic regulation as promoter regions of transcription factors and other genes are 
hypermethylated [50]. This can have implications in tumor development and growth (section 
2.3.2.2 and 2.3.2.3). 
An activation of MAPK pathways can occur indirectly by ROS through the redox sensitive 
targets (section 3.1.1). There are three family members of MAPK; extracellular signal-
regulated kinase (ERK1 and 2); c-Jun NH2-terminal kinase (JNK1, 2 and 3); and p38 (α, β, γ, 
and δ p38-MAPK). They regulate cell proliferation, differentiation, and apoptosis [51].  
Figure 2, Redox modifications on cysteine thiols. Reactive nitrogen species modify the thiol group by 
nitrosylation with NO or forming a nitrothiol involving a reaction with ONOO. In the presence of H2O2, a 
transient and reactive sulfenic acid is formed. Redox modifications leading to glutathionylation can occur 
from the thiol or sulfenic acid depending on GSH/GSSG. In the presence of other thiols, sulfenic acid 
forms disulfide bonds with other cysteine residues. Excessive amount of ROS upon oxidative stress can 
result in irreversible modifications of the cysteine thiol in the form of sulfinic and sulfonic acid. H2O2, 
hydrogen peroxide; GSSG, oxidized glutathione; GSH, glutathione; TXN, thioredoxin; GLRX, 
glutaredoxin, ONOO, peroxynitrite. 
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2.2.3.1 Immune system 
The involvement of ROS in host defense has long been evident as a result of the ability of 
these agents to cause cellular damage. However, an early report showed the induction of the 
T cell growth factor IL-2 in response to low concentrations of O2
• and H2O2 [52]. This 
indicated that ROS also played a role in important signaling pathways in the immune cells as 
well. 
Propagation of microbial killing occurs by the release of ROS by neutrophils and 
macrophages. NOX enzymes of the NADPH oxidase family, found intracellularly and on 
cellular membrane of phagocytes generate ROS upon phagocyte stimulation [17, 53-55]. A 
complex of the NOX2 assembles and translocate towards the membrane before the 
phagosome is fully formed [56]. Depending on its localization, it aids in the release of O2
• 
extracellularly and in phagosomes containing foreign agents. The anion dismutates to H2O2 
spontaneously or enzymatically by SOD or existing myeloperoxidases. Phagosomal 
myeloperoxidases further transform H2O2 to HOCl (Figure 1), a highly potent and toxic 
agent against microbiota relative to other ROS [57]. NOX2 is also localized intracellularly 
where it can form an active complex for ROS generation devoid of translocation towards the 
plasma membrane. This mechanism is potentially involved in intracellular signaling within 
the cell [55]. Strikingly, ROS are also involved in limiting and terminating the immune 
response as well [58]. This is attributed to their ability to suppress pro-inflammatory signals 
and limit the number of immune cells.  
2.2.3.2 Cardiovascular system 
Processes regulated by redox modulations in the cardiovascular system include differentiation 
and contractility of vascular smooth muscle cells, vascular endothelial cell proliferation, 
platelet homeostasis and their activation [36, 50]. Cardiac contraction is affected as calcium 
handling proteins are altered by ROS, leading to changes in intracellular calcium levels.  
2.2.3.3 Thyroid hormone  
A specific type of NOX transmembrane protein is present in the thyroid resulting in the 
release of H2O2. It is used as a co-factor for the enzyme thyroperoxidase in the synthesis of 
thyroid hormones [30].  
2.3 ROS IN PATHOLOGY 
The balance between ROS and antioxidants maintains a redox homeostasis serving to avoid 
adverse physiological manifestations. An imbalance can occur upon excessive production of 
ROS or by decreased ROS scavenging by antioxidant systems. If the changes exceed the cells 
ability to retain a state of homeostasis again, pathologies arise attributed to DNA damage, 
protein and lipid oxidation, and impaired signaling.  
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A substantial decrease in ROS could lead to pathological disorders as well, given the 
important roles they hold in a normal biological setting. The features include disturbed 
immune regulation, lower cognitive function, and hypothyroidism (Figure 3) [17, 30]. 
2.3.1 ROS deficiency  
Evidence of the role of ROS in physiology was mainly facilitated by the findings of the 
pathophysiological signs in patients with chronic granulomatous disease (CGD). The disease 
is characterized by a lack of the NADPH oxidase NOX2 enzymes. Phagocytes are thus 
unable to produce ROS upon stimulation, consequently making these patients highly prone to 
infections [17, 30, 59]. Other implication in CGD patients have been reports of lower 
cognitive function [60]. Surprisingly, hyper-inflammation is implicated with NOX deficiency 
as well. The mechanism remains poorly understood but has in part been assigned to the 
impairment in degradation of phagocytosed material, leaving the cells persistently activated 
[58].  
Hypothyroidism is associated to impaired ROS production as evident by the use of H2O2 in 
the synthesis of thyroid hormones T3 and T4 (section 1.2.6) [30]. 
2.3.2 Excessive ROS 
Deleterious effects in cells and tissue occur upon excessive production of ROS or at 
impairments in antioxidant systems. Cellular damage in this setting arises from DNA 
modifications, lipid and protein peroxidation [61, 62]. Pathophysiological consequences 
Figure 3, Implications of ROS levels in health and disease. Processes of the immune system and signaling 
cascades are effected upon impairments in ROS-generation. Diseases included are chronic granulomatous 
disease characterized by a deficiency in NOX2 ROS generating enzyme and hypothyroidism as thyroid 
hormone production is impaired.  
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where ROS have been implicated include ischemia and reperfusion injury [63-65] (section 
1.3.2.1), atherosclerosis [36], neurodegenerative diseases [66-69], and cancer [70-72] 
(sections 1.3.2.2 and 1.3.2.3).  
2.3.2.1 Ischemia and reperfusion 
Xanthine dehydrogenase (XDH) is a hydroxylase involved in the metabolism of purines. At 
normoxic conditions, it converts hypoxanthine, an ATP metabolite, to xanthine and 
subsequently uric acid by the use of NAD+ [73]. It was first proposed in 1981 that ischemia 
also leads to the conversion of XDH to xanthine oxidase (XO) in the small intestine. The 
latter, in turn, elicits production of ROS upon reperfusion and cause cellular damage [65, 74]. 
The mechanism involves accumulation of the purine metabolites, adenosine, inosine, 
hypoxanthine, and xanthine as the cell loses its ability to resynthesize ATP at ischemia. The 
limitation of ATP also leads to increased cellular Ca2+ as the ATP dependent Ca2+ channels 
are impaired. Proteolytic conversion of XDH to XO occurs due to the high levels of 
intracellular Ca2+ [75]. Molecular oxygen delivered to the ischemic site at reperfusion reacts 
with Hypoxanthine and XO forming superoxide [76] and its derivatives (Figure 4). 
 
 
 
Besides the increased ROS production, ischemia and reperfusion reduces levels of GSH with 
an increase in GSSG (oxidized GSH in disulfide form) [77-79]. Additional antioxidants 
shown to be reduced in an ischemic setting are SOD, glutathione peroxidase and ascorbate 
[80]. Hence, the contribution of oxidative stress is accelerated in ischemia and reperfusion by 
increased ROS generation and an impairment in their reduction and scavenging. 
Figure 4, ROS production in ischemia and reperfusion by xanthine oxidase. In a normal physiological 
setting, xanthine dehydrogenase facilitates the metabolism of hypoxanthine and xanthine to uric acid by the use 
of NAD+. Xanthine dehydrogenase is cleaved to xanthine oxidase at low oxygen levels. At reperfusion there is a 
burst of molecular oxygen entering the ischemic site. The enzyme xanthine oxidase will metabolize 
hypoxanthine and xanthine at the expense of oxygen, generating superoxide as a byproduct.  
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2.3.2.2 Carcinogenesis 
ROS-mediated DNA damage has been implicated in cancer for half a century [70-72]. 
Markers for ROS-mediated DNA damage is mainly measured by oxidation of DNA [81]. It is 
important to note that while oxidation can impair DNA function, a basal level of oxidized 
bases exists in a normal setting. These are normally reduced by repair systems. However, 
upon excessive oxidative stress, damages occur on the DNA leading to mutations or altered 
gene expression [61]. Alterations involving oncogenes or tumor suppressor genes can 
promote tumor initiation.  
ROS retain the ability to induce modifications on all bases in DNA, however, not all 
alterations result in mutations. Modified guanine primarily mispairs with adenine during 
replication while modified adenine does not result in in mispaired bases [82]. Thus, the 
majority of mutations by ROS seen in tumors exhibit guanine to thymine transversions [83, 
84]. This is evident in hotspot mutation regions of the KRAS oncogene [85-88] and the TP53 
tumorsuppressor gene [89-91], both of which exhibit several GC to AT base pair 
substitutions.  
Further corroborating the role of ROS in carcinogenesis is the presence of oxidized DNA in 
patients with chronic hepatitis [92], which is a major risk factor for the development of 
hepatocellular carcinoma (HCC). Additionally, transgenic mouse model of hepatitis destined 
to develop HCC displays high amounts of oxidative DNA damage in the same manner [93].  
The MAPK pathway modulates a variety of cellular processes by phosphorylation of 
transcription factors. The elicited responses include proliferation, differentiation, and 
apoptosis, all important factors in carcinogenesis. The ERK subfamily is mainly associated to 
proliferation and a balance between the levels of ERK and JNK activation mediates cell 
survival. As ERK decreases with an increase in JNK pathway signaling, cells undergo 
apoptosis [51]. Proliferation is regulated through activation of AP-1 transcription factor ( 
JUN/FOS) which in turn activates CCND1 and results in entry into cell cycle division [72].  
As mentioned previously, ROS regulate the transcription factor NFKB by its redox sensitive 
inhibitor, IKB. NFKB has a role in inflammation, differentiation, and cell growth. The genes 
it regulates promote cell transformation, angiogenesis, and proliferation and thereby linked its 
activity carcinogenesis. Chronic inflammation plays a role in carcinogenesis as well, due to 
the relation of ROS-production at site of injury [94]. 
LUNG CANCER 
Serial smokers have high risk of developing lung cancer. The smoke of a cigarette contains 
several carcinogens and high levels of ROS. Lung cancer tissue displays increased oxidative 
DNA damage compared to surrounding tissue [95]. This is corroborated by the finding that 
cells exposed to cigarette have higher oxidative DNA damage [96]. Smokers exhibit 
dramatically high levels of urinary 8-oxoDG, a measurement of oxidative DNA damage to 
guanine bases [97]. 
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LIVER CANCER 
Chronic hepatitis, a major etiological risk factor for the development of liver cancer and 
present with DNA oxidative damage [92, 93]. HCC displays predominantly GC to AT base 
substitutions in hotspot regions of TP53 [98]. 
PANCREATIC CANCER 
Reduced antioxidant capacities along with increased oxidative stress are present in patient 
with pancreatic adenoma carcinoma (PDAC) and chronic pancreatitis [99]. A connection 
between oxidative stress and tumor progression upon loss of TP53 function is also prevalent 
in this cancer [100]. 
BREAST CANCER 
DNA damage mediated by ROS alterations is present in inflammatory breast disease [101], 
where potential malignant transformation can occur. Additionally, invasive ductal carcinoma 
of the breast shows DNA damage consistent with oxidative attack [102].  
2.3.2.3 Angiogenesis, invasion, and metastasis  
Cancer cells with high metastatic capabilities exhibit increased levels of ROS, contributing to 
angiogenesis, invasion, and metastasis. Proteins and signaling pathways associated with 
invasiveness and metastasis are implicated with ROS-regulation or damage elicited by higher 
levels of oxidative stress [103-105].  
The main regulators of the transcriptional response to low oxygen levels are the hypoxia-
inducible factor (HIF) proteins [106, 107]. Translocation to the nucleus occurs as a 
heterodimer consisting of an ubiquitination-regulated α subunit and a constitutively expressed 
β subunit [108]. Activation of the HIFα occurs by ROS-mediated inhibition of its proteolytic 
cleavage. H2O2 inhibits the activity of prolyl hydroxylase, the enzyme mediating proteolysis 
of HIFα [109, 110]. Besides the protective roles of HIF for compensatory mechanisms at low 
oxygen tension, it is implicated in the initiation of cancer and subsequent tumor progression 
[111]. Invasive characteristics are acquired by cancer cells by interactions of ROS and HIF 
[112, 113]. 
Vascular remodeling, and in some instances angiogenesis, take place in response to 
chemotactic factors inducing proliferation and migration of vascular smooth muscle cells. 
This chemotactic response is H2O2 dependent [114, 115]. An additional redox regulated event 
in vascular remodeling is the activity and expression of matrix metallopeptidases (MMPs). 
For the formation of new vessels, MMPs degrade the extracellular matrix to facilitate the 
migration of vascular cells. H2O2 and ONOO induce MMP-2 and MMP-9 while NO reduce 
their levels [116]. An additional proangiogenic factor is the vascular endothelial growth 
factor (VEGF) and the VEGF receptors. The VEGF receptor tyrosine kinase activity is 
regulated via intramolecular disulfides of its cysteine residues [117]. The receptor, upon 
activation, induces ROS as downstream mediators of angiogenic-signaling [118].  
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2.3.3 ROS and cancer therapy 
Given the damage elicited by excessive levels of ROS, antioxidant drugs were produced to 
circumvent the harmful effects. One example is sulphasalazine, a drug used as a free radical 
scavenger [119, 120] in inflammatory bowel disease. Antioxidant supplements were also 
investigated in prevention studies, however, many of these reports show contradictory results. 
Serious limitations with peroral administration of antioxidants include the problems with in 
vivo dosage levels, other dietary sources of antioxidants interfering with findings, delivery of 
specific antioxidants to subcellular localizations [36]. An additional complication upon the 
supplementation of antioxidants is the high non-physiologically relevant doses that can have 
adverse effects in the general balance of intracellular antioxidants. Several non-enzymatic 
antioxidants also depend on each other for activity, thus, introducing one in excess might not 
elicit the desired response.  
In many instances, antioxidant therapy in cancer is ineffective as the tumor is already 
established and can to some extent self-sustain by the oncogenic properties acquired, 
regardless of ROS scavenging. Coincidentally, tumor cells might harness antioxidant activity 
to favor its growth and malignancy. Another approach to cancer therapy is to elicit more ROS 
in tumor cells, leading to activation of cell death pathways [121]. Cancerous cells exhibit an 
increased basal level of ROS compared to normal cells. This adaptation favors malignancy 
(section 1.3.2.2 and 1.3.2.3), however, it renders the cells more vulnerable to subtle changes 
in ROS levels [122]. Conventional chemotherapy and ionizing radiation induce the 
generation of ROS by both direct means or indirectly through interactions with important 
cellular processes. Once the ROS level of the cell exceeds the threshold for tolerance, cell 
death is triggered (Figure 5). A new emerging alternative treatment approach also utilizing 
this event are selenium based medical therapeutics (more in chapter 4). 
 
 
 
 
  
 
 
Figure 5, Basal levels of ROS in benign and malignant cells. The higher levels of ROS in malignant cells 
render them more sensitive to additional oxidative insult. This is termed as the “threshold concept”, utilized 
by various therapeutic agents. Modified from Misra et al.  [123] 
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2.3.3.1 Cytostatic agents 
Cytostatic agents target cellular pathways in cell cycle and metabolism, utilizing the higher 
rates of proliferation in tumor cells in relation to normal cells. Several blood cancer diseases 
were treated with cytostatic agents during the 1940s before their mechanism of action was 
elicited [124]. The use of a folate antagonist showed effects in the treatment of leukemia in 
children[125]. Since then, several types of cytostatic drugs have been developed, primarily 
classified in four groups; antimetabolites, alkylating agents, mitotic inhibitors, and 
topoisomerase inhibitors. This class of drugs include antimetabolites, targeting the S phase of 
cell cycle by incorporation into DNA as a non-functional nucleoside. Alkylating agents, 
introducing interstrand cross-linking in DNA and interference with protein synthesis. Mitotic 
inhibitors, disturb the formation of microtubule in mitosis. While disruption of DNA torsion 
during replication is inhibited by topoisomerase inhibitors. The reported effects of many 
cytostatic drugs leading to cell death is mediated through increased ROS levels [126]. Among 
the ROS-mediated effects upon drug administration are for example modulation of NOX 
enzymes, GSH depletion, or TP53 activation via the p38 MAPK pathway [126-129].   
2.3.3.2 Ionizing radiation therapy 
Another therapeutic approach based on ROS-generation is ionizing radiation therapy. It is 
estimated that around 50% of patients might benefit from radiation therapy [130]. However, a 
major complication with this approach is the damage elicited on skin upon radiation exposure 
[131]. 
2.3.3.3 Targeted therapy  
Monoclonal antibodies, small molecule tyrosine kinase inhibitors, and immunotherapy drugs 
are within the class of targeted therapy. Initially thought to have single target sites, many 
targeted therapy drugs displayed multi-faceted effects with some mediated by ROS [132, 
133]. Depending on which drug is used, results show an increased O2
• production, NOX 
impairment or reduction in intracellular GSH levels upon treatment. 
2.3.3.4 Drug resistance  
Drug resistance against chemotherapeutic agents remains a major problem in a clinical 
setting. There are several mechanisms for this acquired drug resistance, including, but not 
limited to, detoxification mechanisms of drugs, altered uptake or upregulation of efflux 
pumps, modifications of target sites [134-136]. 
MULTIDRUG RESISTANCE PROTEINS  
Membrane bound ATP-binding cassette (ABCC) transporter proteins, previously known as 
multidrug resistance protein (MRP), are involved in the efflux of various substrates including 
administered chemotherapeutic drugs [137-139]. Some reports show a dependence on GSH 
for propagation of efflux by ABCC [140]. Tumor cells exhibit an upregulation of ABCCs in 
various instances as a mechanism of intrinsic or acquired drug resistance [141]. 
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CYSTINE/GLUTAMATE ANTIPORTER 
Overexpression of GSH confers drug resistance in cancer cells as it is involved in cellular 
protective mechanisms and in the detoxification of many drugs [142]. An important limiting 
step in GSH biosynthesis is the availability of the cysteine [143]. Provision of this amino acid 
is facilitated by the cystine/glutamate antiporter, or more commonly known as the xc system 
[144]. The antiporter is comprised of a heavy and light chain, solute carrier family 7 member 
11 (SLC7A11) and solute carrier family 3 member 2 (SLC3A2), respectively. Cystine is 
taken in to the cell in exchange for a glutamate by the xc system. The cystine is reduced to 
cysteine intracellularly where it can enter GSH biosynthesis. Overexpression of xc system 
has been reported in various cancer cells [145, 146]. Interference with cystine uptake by the 
addition of glutamate or specific siRNA mediated inhibition of the antiporter which resulted 
in an increased sensitivity towards chemotherapeutic agents [145]. Inhibitors of GSH 
mediated the same effect, indicating towards the importance of this system in drug resistance 
of cancer cells.  
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3 KEY REDOX REGULATORY ENZYMES 
Cellular defense against excessive ROS by antioxidants is imperative for the preservation of 
redox homeostasis. Non-enzymatic scavengers of ROS exist, primarily supplied from dietary 
sources. Examples are vitamin E (tocopherol), vitamin A, and vitamin C (ascorbic acid) 
[147]. Enzymatic antioxidants include SOD, and the H2O2 reduction agents, catalase and 
PRDX. An additional essential antioxidant is the low molecular weight tripeptide GSH.  
Thioredoxin (TXN) and glutaredoxins (GLRX) systems also play a major role in reducing 
disulfide bonds in target proteins and thus, maintains the redox balance. Many of the 
antioxidant enzymes have several isoforms and can differ in their subcellular localization, 
implicating the importance of ROS-regulative mechanisms.  
The response against ROS is initiated by the transcriptional element ARE [148, 149]. 
Activation of ARE occurs mainly by binding of the NFE2L2 transcription factor [150, 151]. 
In a physiologically healthy setting the NFE2L2 is inhibited by interaction with KEAP1 
[152]. Dissociation of the KEAP1 occurs by redox modulation, primarily as a response to 
oxidative stress [48, 49, 153].  
The NFE2L2 mediates a response by the expression of Phase I and II metabolizing enzymes 
[154] as well as controlling levels of ABCC transporters [155]. One of the key components 
regulated by this transcription factor is the xc system, providing the cell with cystine for the 
synthesis of GSH [142, 156, 157]. NFE2L2 also induces the expression of NADPH 
oxidoreductases, some of which belong to the TXN family of proteins [158, 159]. Besides the 
regulation of antioxidant enzymes, NFE2L2 facilitates propagation of the pentose phosphate 
pathway for increased levels of NADPH [154]. 
3.1 THE THIOREDOXIN FAMILY OF PROTEINS 
The thioredoxin superfamily of proteins possesses an evolutionary conserved structural 
thioredoxin-fold and an active site which primarily includes a C-X-X-C residue, essential for 
the proteins’ functionality as oxidoreductases [160, 161]. TXN and GLRX are two thiol 
bearing proteins within this superfamily with nucleophilic qualities. Electrophiles (or the 
oxidized target protein) are reduced in a SN2 nucleophilic substitution reaction by these 
proteins in particular [162]. As the disulfide bond of the target protein is reduced, the 
oxidoreductase in turn is inactivated by the formation of an intra-disulfide bond. The 
subsequent reduction of the enzymes uses NADPH (Figure 6). 
3.1.1 The Thioredoxin System 
The TXN system consists of the ubiquitously expressed TXN, the selenoprotein thioredoxin 
reductase (TXNRD), and NADPH. As TXN reduces a disulfide bond on a target protein it is 
inactivated in its oxidized form. It is reduced by TXNRD at the expense of its own reduced 
state. NADPH is used as a hydrogen donor to in turn reduce the oxidized TXNRD (Figure 
6).   
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The TXN protein was first discovered as a regulator of DNA synthesis by donating a 
hydrogen to ribonucleotide reductase [163]. In mammals, there are two isoforms of the 
protein, a cytoplasmic TXN1 and a mitochondrial TXN2 [164]. As such, TXNRD exists as 
cytoplasmic and a mitochondrial form as well, TXNRD1 and 2 respectively. Besides the role 
in DNA synthesis, TXN proteins regulate transcription factors like NF-κB and TP53. The 
proteins are also implicated in the inhibition of apoptosis by redox-dependent interaction 
between TXN and mitogen-activated protein kinase kinase kinase 5 (MAP3K5) or also 
known as the apoptosis signal-regulating kinase 1 (ASK1) [165]. MAP3K5 initiates 
downstream signaling JNK/p38 MAPK pathway involved in cell death. The TXN1 protein 
inhibits the activation of MAP3K5 by binding interaction. Upon oxidative stress, TXN1 is 
oxidized leading to its dissociation from the MAP3K5. TXN2 in turn regulates mitochondrial 
apoptosis by the inhibition of cytochrome c release [166]. 
Increased levels of TXN or TXNRD are present in several different tumors [167-169] and 
associated with drug resistance [170] and worse prognosis [171-173]. Given the relation of 
TXN in various cancer types, implementation of TXN as a biomarker for cancer has been 
proposed [174].  
3.1.2 The Glutaredoxin System 
The small oxidoreductase GLRX belongs to the thioredoxin superfamily of proteins due to 
the thioredoxin-fold structure it encompasses. The system entail the GLRX,  GSH tripeptide 
(γ-glutamyl-cysteinyl-glycine), glutathione S-reductase (GSR) and NADPH [175, 176]. The 
initial disulfide bond cleavage occurs in the same manner as for the TXN protein. Oxidized 
GLRX is reduced by 2 GSH molecules, resulting in the formation of GSSG. GSR is 
responsible for reducing the GSSG, and then utilizes NADPH as a hydrogen donor for its 
reduction. (Figure 6). Processes regulated by the GLRX system include redox modulation by 
interactions with thiols. This in turn regulates differentiation, modulation of transcription 
factors, and cell death pathways. As with TXN, GLRX is important for DNA synthesis as 
well by facilitating reduction of ribonucleotide reductase [177]. The different mammalian 
isoforms include GLRX1, 2, 3 and 5, and they differ in their subcellular 
compartmentalization. GLRX1 and 3 are cytosolic while GLRX5 is mitochondrial. The 
GLRX2 protein is found as three splice forms, namely GLRX2a, GLRX2b, GLRX2c, 
situated in the cytosol, nucleus, and mitochondria, respectively [178, 179].   
3.1.2.1 Glutathionylation 
The GLRX proteins contain a GSH-binding 
moiety which allows them to exist in three 
oxidation states, a dithiol, an internal disulfide 
or a third,  glutathionylated form [180]. Thus, 
the protein possesses monothiol and dithiol 
reduction mechanisms.  
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Figure 6, Thioredoxin and glutaredoxin systems. Oxidized protein thiols in the form of disulfides are 
reduced by the oxidoreductases TXN and GLRX. The target protein is reduced at the expense of the reduced 
state of the oxidoreductase generating an inactive oxidized enzyme. The TXN is reduced by the selenoprotein 
TXNRD which forms a Se-S bond its oxidized state. NADPH from the pentose phosphate pathway reduces 
TXNRD. GLRX is reduced by 2 GSH molecules, generating GSSG. This in turn is reduced and once again 
activated by GSR. As with the TXNRD, the GSR utilizes NADPH for its reduction. TXN, thioredoxin; 
TXNRD, thioredoxin reductase; GLRX, glutaredoxin; GSH, glutathione; GSSG, oxidized disulfide 
glutathione; GSR, glutathione S-reductase. 
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The dithiol mechanism uses both cysteine thiols of the GLRX active site where the N-
terminal Cys approaches a disulfide on a substrate by nucleophilic attack. A mixed disulfide 
intermediate is formed with subsequent attack by the C-terminal Cys of the GLRX. The 
released substrate is reduced while the GLRX is in its oxidized form with an internal 
disulfide. The monothiol reduction involves an attack against a glutathionylated protein (P-
SG) or GSH. This gives rise to the glutathionylated GLRX form which can be further reduced 
by a second GSH molecule [180, 181]. By these means GLRS also regulates S-
glutathionylation and deglutathionylation of proteins, a process important in regulating the 
activity of certain enzymes and transcription factors [176]. 
Much like the TXN1, GLRX1 associates with MAP3K5, regulating the response to apoptosis. 
Attenuation of GLRX2 sensitized cells to apoptosis while induction of the isoform had a 
protective effect [182, 183]. Several of the isoforms are found to be upregulated in cancers 
[176, 184, 185] and relate to increased drug resistance [186]. 
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4 SELENIUM IN REDOX BIOLOGY 
Selenium is an essential trace element first discovered by the Swedish chemist Jöns Jacob 
Berzelius in 1817. Berzelius was a part owner of a chemical factory in Gripsholm that 
purified sulfur from iron pyrite. During the purification process a red precipitate appeared. 
After investigation, Berzelius discovered that the red precipitate was a new element and 
named it selenium after the Greek word for moon, σελήνη [187].  
4.1 SELENOPROTEINS 
Over 50 years ago the genetic code was deciphered, giving insight on translational processes 
of genetic information [188]. The different nucleotides of a cell are used in three letter code 
combinations, where certain codons specify the insertion of an amino acid by the recruitment 
of tRNA, while three codons exist to terminate translation. The latter are termed stop codons 
and consist of the UAA, UAG and the UGA. As the protein synthesis machinery reaches one 
of them, they are recognized by a termination factor as opposed to a specific tRNA [189]. 
Exceptions exist to this with the most interesting one being the recognition of the 21st amino 
acid selenocysteine (Sec) by the UGA stop codon [190]. Selenocysteine Insertion Sequence 
(SECIS) element is a unique structure residing in the untranslated mRNA of selenoproteins. 
Binding of SECIS to the SECIS element binding protein-2 (SECISBP2) [191] forms a 
complex with selenoprotein-specific elongation factor (EEFSEC) [192]. This allows for the 
UGA codon be recognized as Sec insertion and initiates the recruitment of tRNA[Ser]Sec. A 
unique feature of Sec is its synthesis on the specific tRNA from a serine intermediate upon 
the formation of the specific SECIS binding complex.  
The mRNA of selenoprotein P (SELENOP) has two SECIS elements with 10 UGA codons 
resulting in several Sec insertions. This is important as SELNOP is suggested to be 
responsible for the transportation of selenium from the liver to other organs in the form Sec. 
The intracellular enzyme selenocysteine lyase (SCLY) cleaves the Sec to selenide, in order to 
facilitate the synthesis of new selenoproteins [193]. 
There are 25 selenoproteins in humans, although some are well characterized, the function of 
most of them remain unknown. Two of the most studied selenoproteins are the TXNRD and 
the GPX isoforms. GPX was the first selenoprotein discovered [194] and had long been 
assigned antioxidant capabilities for its role in the reduction of hydroperoxides to their 
corresponding alcohols [14]. The TXNRD is part of TXN system, essential for reduction of 
disulfides in proteins (as mentioned in detail; section 3.1). 
4.2 SELENIUM METABOLISM  
The main dietary intake of selenium is in the organic forms of selenomethionine (SeMet), 
Sec, and methylselenocysteine (MSC). Inorganic forms of selenium include selenate, and 
selenite. Selenium compounds are metabolized differently depending on the parent species 
and result in three endpoints, a) incorporation in selenoproteins as Sec, b) non-methylated 
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redox active selenium metabolites, like selenide, and c) methylated redox active selenium 
compounds, like methylselenol [195].  
SeMet generates Sec through the trans-selenation pathway. MSC and SeMet are cleaved by 
β-lyases and γ-lyases respectively for the formation of methylselenol. However, the γ-lyases 
acitivity in mammals for the metabolism of SeMet is very low. Selenate is reduced to selenite 
and both forms lead to the selenide (HSe) metabolite, required for tRNASec during 
selenoprotein synthesis. Selenite is highly reactive and can also give rise to 
selenodiglutathione (GSSeSG) upon reaction with GSH. The GSSeSG also serves as an 
intermediate in the formation towards HSe by reaction with TXN and GSR [196-198] 
(Figure 7). 
Selenium toxicity was first discovered almost a century ago in livestock that consumed high 
selenium containing plants [199]. Pathological attributes are present at selenium deficiency 
due to impairment in physiological processes that involves selenoproteins, however, once the 
proteins are saturated with selenium, toxicity arises. This trait is exploited in a preclinical 
setting involved in the development and use of selenium compounds as cancer therapeutics 
[123].  
4.3 SELENIUM COMPOUNDS AS MEDICAL THERAPEUTICS 
Effects of selenium in disease prevention has long been studied due to the element’s 
antioxidant properties. Low dose selenium supplementation has shown cancer preventative 
effects [200, 201], protection against the development of inflammatory disturbances [202], 
and heart disease [203]. These properties are mainly attributed to selenium incorporating in 
selenoproteins, such as the TXNRD or GPX, eliciting antioxidant activity [204].  
Many sulfur compounds have an equivalent selenium analogue interesting for the use as 
redox active agents. The higher reactivity of the selenium analogues as opposed to the S-
compound is explained the higher nuclephilicity of selenium [205] and the low pKa value of 
the selenols (SeH) compared to the corresponding thiol [206]. Two of the selenium 
compounds showing highest efficacy against tumor cells are selenite and MSC, the selenium-
analogues of Sulphite and methyl cysteine, respectively.  
High doses of selenium, exceeding the requirement of dietary intake, elicits prooxidative 
effects. This is mainly mediated by the metabolites HSe and methylselenol [207], generating 
ROS by their ability to redox cycle with thiols and NADPH systems [197, 208, 209]. 
Downstream responses include activation of caspases dependent and independent cell death 
[210], inhibition of angiogenesis [211], anti-proliferative effects [212]. 
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Figure 7, Selenium metabolism. Thiol homeostasis is kept by the influx of oxidized cystine via the xCT 
antiporter. The cystine is reduced intracellularly to cysteine and used for GSH synthesis and other biological 
processes.  SeO32 can be reduced to HSe extracellularly by cysteine that is transported out of the cell through 
MRP/ABCC. Intracellularly, SeO32 redox cycles with the TXN and GLRX system or react with GSH to form 
HSe. The metabolite in turn can be used in for formation of the tRNASec for selenoproteins biosynthesis. In the 
presence of SAM, the HSe forms CH3Se. Se-methylselenocysteine forms the CH3Se metabolite by β-lyase 
cleavage. Selenomethionine on the other hand needs γ-lyase cleavage. Selenomethione can also generate 
selenocysteine through the trans-selenation pathway. SeO32, selenite; GSH; glutathione; HSe, selenide; ABCC, 
ATP Binding Casette family C; TXN, thioredoxin; TXNR, thioredoxin reductase; GSR, glutathione S-reductase; 
GLRX, glutaredoxin; CH3Se, methylselenol; xc-, cystine/glutamate antiporter xc system 
Figure modified from Wallenberg et al [195] 
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4.3.1 Selenite 
Perorally administered selenite will be reduced as early as in the gastric mucosa, due to its 
high reactivity. Thiols are important for the reduction of selenite and the compound redox 
cycles efficiently with GSH leading to the generation of O2
• [213]. Selenite was also found 
to be a substrate for the TXN [208] and GLRX [209] systems, forming the metabolite 
selenide which can further redox cycle to elemental selenium [214]. Cellular consequences 
can include a reduction of cellular thiols, oxidative modulations of redox sensitive receptors 
or transcription factors (section 2.2.3), and ROS generation.  
One of the most favorable traits of selenite is its ability to induce cell death in tumor cells 
while rendering the benign cells unharmed [215-217]. Tumor cells have an inherently higher 
basal level of ROS compared to normal cells, allowing for an additional markup to push the 
tumor cells over the threshold for cell death (as highlighted in figure 5, section 2.3.3). 
Secondly, the uptake of selenite differs between benign and malignant cells. Sensitivity 
towards selenite was found to be correlated to an enhanced reduced extracellular environment 
mediated by the xc system and ABCC [146]. Tumor cells upregulate the antiporter in order 
to sustain the elevated demand of GSH in the highly metabolically active cell. Another 
occurrence in tumor cells is the upregulation of ABCC efflux pumps. These will facilitate an 
enhanced excretion of cysteine, facilitating a reduced extracellular environment. In the 
presence of selenite, a reduction occurs to the highly reactive selenide metabolite which is 
readily taken up by the cell (Figure 8). 
 
 
4.3.1.1 Cellular targets  
Different cell death pathways are ascribed to selenite exposure ultimately leading to 
apoptosis. Specifically, apoptosis in cervical cancer cells was mediated by TP53 and cyclin 
dependant kinase 5 regulatory subunit 1 (CDK5R1) caspase independent pathway [218]. In 
NB4 cells, selenite induced ROS generation with ER stress, and apoptosis was mediated 
PI3K/AKT signaling and by inhibition of autophagy [219]. 
  
Figure 8. Reduced extracellular 
environment enhances sensitivity towards 
selenite. Cystine is taken up for the synthesis 
of GSH by upregulated xc system. Cystine is 
reduced to cysteine and transported out of the 
cell causing a reduced extracellular 
environment. This in turn results in the 
reduction of SeO32 to HSe, which is more 
readily taken up by the cell. SeO32, selenite; 
HSe, selenide; xc, cystine/glutamate 
antiporter; MRP, multidrug resistant protein; 
GSH, glutathione 
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4.3.2 Methylselenocysteine 
The naturally occurring organic MSC was first identified in 1960 from selenium containing 
plants [220]. The compound is non-toxic in its parent form, while its metabolism generates 
several highly reactive compounds.  
4.3.2.1 Enzymatic cleavage 
Cysteine-S-conjugate β-lyases cleave carbon-sulfur bonds into their corresponding α-keto 
acid, in pathways related to detoxification of xenobiotics [221]. These enzymes also cleave 
the selenium-analogues of the sulfur substrates, and at a higher affinity due to the high 
nucleophilicity of Se compared to S and the low pKa of the selenol compared to the thiol 
[222, 223]. The kynurenine aminotransferases (KYATs) are an example of such cysteine S-
conjugate β-lyases with the ability to metabolize MSC [224]. KYATs hold dual enzymatic 
activity with transamination and β-elimination activity depending on the substrate and the 
presence of the α-keto acid co-substrate. Methylselenol is formed upon β-elimination of MSC 
while transamination results in methylselenopyruvate (MSP). In general, KYATs favor 
transamination over β-elimination with several substrates. However when MSC was used as a 
substrate for recombinant KYAT1, the results showed an opposite feature [225].  
 
KYATs are pyridoxial 5’-phosphate (PLP) dependent enzymes where the PLP is converted to 
a pyridoxamine 5’-phosphate (PMP) intermediate in a half-transamination reaction. The 
presence of an α-keto acid is required for the regeneration of PLP from the intermediate. 
During a β-elimination reaction propagated by the enzyme, PLP is utilized without the 
formation of an intermediate. 
4.3.2.2 Cellular targets 
The MSP metabolite has certain anti-tumoral effects as it structurally resembles the HDAC 
inhibitor butyrate. [226, 227]. Methylselenol is highly volatile and elicits several anti-
neoplastic effects [228] leading to cell cycle arrest and apoptosis [229]. 
The methylselenol metabolite is a better substrate to the TXN and GLRX systems than 
selenide, leading to increased redox cycling [230].  MSC mediated apoptosis occurs through 
caspase activation in a TP53 independent manner [231]. This can have beneficial 
implementation in a clinical setting as many tumors exhibit with TP53 impairments.  
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5 CANCER 
Cellular growth is tightly regulated in tissue and a dysregulation favoring uncontrolled 
division confers malignancy in the form of a tumor. Various traits need to be acquired by a 
cell for malignant transformation [232], some of the most important drivers being the 
continuous stimuli by oncogenes and silencing of important physiological tumor suppressor 
genes, i.e. KRAS and TP53 respectively.     
5.1 HEPATOCELLULAR CARCINOMA 
Liver cancer accounts for the second most common cancer-related death in the world [233]. 
The majority of hepatocellular carcinomas (HCC) are diagnosed at late stages of the disease. 
Liver resection and transplantation are not the first treatment options in these cases, and 
recurrence is very high in patients actually receiving a resection [234]. Some of the major risk 
factors for the development of HCC are underlying liver diseases such as chronic hepatitis, 
alcohol-related liver disease, and non-alcoholic steatohepatitis [235-237].  
HCC has a TP53 mutational hotspot [98] and displays G to T transversions associated with 
oxidative stress [89, 238] (section 2.3.2.2). Additional dysregulated oncogenes and tumor 
suppressor genes in HCC include KRAS, CDKN2A, PIK3CA, and PTEN [239]. 
Chemotherapeutic agents have not been shown to improve the outcome for HCC patients. 
The first line of treatment is through molecular targeted therapy by multi-kinase inhibitor 
sorafenib [240, 241]. By inhibition of several kinases, sorafenib regulates processes in tumor 
proliferation and angiogenesis.  
5.2 PANCREATIC ADENOCARCINOMA 
Pancreatic cancer accounts for the fourth most common cancer-related death and it is 
estimated to rank second within the next decade [242, 243]. Pancreatic adenocarcinoma 
(PDAC) is the most common type of malignant tumors originating from pancreatic tissue. 
Patients exhibit with a 5-year survival rate of less than 6% [243, 244]. PDAC are usually 
diagnosed at very late stages and are accompanied by a high potential for metastasis and 
high drug resistance [245]. Risk factors for the disease are tobacco smoke, chronic 
hepatitis, diabetes mellitus 2, high alcohol consumption, and obesity [245, 246].  
The most common mutations in PDAC are in the oncogenes and tumorsupressor genes; 
KRAS, CDKN2A, TP53 and SMAD4 [247, 248]. Targeted therapy against these commonly 
aberrated genes in pancreatic cancer are not in use. The most common line of therapy is 
cytostatic agents as many patients display with a disease that is unsuitable for surgical 
removal. Gemcitabine has long been in use as first line treatment for PDAC, however, 
intrinsic and acquired chemo resistance are common [134]. Recently, the clinical use of 
FOLFIRINOX was implemented after it was shown to have beneficial effect over the use of 
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gemcitabine as a single agent [249]. The combination chemotherapy regimen consists of 
oxaliplatin, irinotecan, 5-fluorouracil, and leucovorin.  
5.3 SELENIUM COMPOUNDS IN CANCER THERAPY  
Selenite was used over 50 years ago for tumor localization as it was shown to accumulate in 
neoplasms of the brain and thorax upon i.v administration of 75Se. [250]. Since then there 
have been several reports demonstrating the enrichment of selenium in organs. Suzuki et al 
[251] used labeled selenium sources of MSC, SeMet, and selenite, to investigate their 
bioavailability and distribution in major organs. The authors found uptake of selenium in 
kidney liver and spleen. MSC also sowed enhanced uptake in pancreas and duodenum in 
comparison to the other two selenium compounds. 
Our group has been the first to perform a phase I clinical trial in human with sodium selenite. 
The maximum tolerable dose was set to 10.2 mg/m2 where patients exhibited a mean plasma 
concentration of 23 µM [252]. The results of the trial showed beneficial effects can be 
achieved by doses that have low adverse side effects. The efficacy of i.v administered selenite 
in combination with chemotherapeutic drugs merits further investigation. Animal models 
show a protection against nephrotoxicity induced by cisplatin upon selenite pretreatment 
[253]. Selenium supplements given to patients with ovarian cancer receiving cisplatin post-
surgical resection, showed lower adverse effects that are usually associated with cisplatin 
treatment [254]. These results are in line with the finding that MSC protects against organ 
toxicity and potentiated the effect of cytostatic agents in preclinical animal models [255]. 
MSC also potentiates the effect elicited by modulated gemcitabine in targeted therapy [256]. 
Benefits of using MSC or selenite in combination with chemotherapeutic agents could thus 
limit adverse effects and allow for a broader therapeutic window.  
Several cytostatic drugs mediate their effect through a single pathway. This renders risks for 
the development of drug resistance in cancer cells. The ability retained by redox active 
selenium compounds to elicit a multi-target response favors them for the use as medical 
cancer therapeutics [210].  Not only do selenium compounds have low risk for the 
development of resistance, they tend to be more efficient cells with resistant phenotypes 
(section 4.3.1). Both selenite and MSC are potent anti-cancer agents with differing modes of 
actions. Selenite would be highly effective against tumor cells with upregulated ABCC 
transporter proteins, due to the reduced extracellular environment enhancing the uptake of 
selenide. On the other hand, cells harboring mutated or non-functional TP53 can be targeted 
by MSC as it elicits a TP53 independent mode of cell death [231].  
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6 AIM OF THESIS 
6.1 OVERALL AIM 
To further enhance our understanding of the expression patterns of redox proteins in tissues 
associated with oxidative stress and to implement the use of redox active selenium 
compounds in cancer therapy in liver and pancreas. 
6.2 SPECIFIC AIMS  
1. To investigate the levels of thioredoxin and glutaredoxin proteins in hepatocellular 
carcinoma compared to surrounding non-cancerous tissue with correlations to clinical 
parameters.  
2. To evaluate the cellular and ultrastructural changes at ischemia and reperfusion in 
human liver tissue and potential effects on thioredoxin and glutaredoxin proteins.  
3. To enhance the growth inhibitory effects of the redox active selenium compound, 
methylselenocysteine, by modulation of its metabolizing enzymes in hepatocellular 
carcinoma cell lines. 
4. To compare the response of selenium compounds in conventional in vitro 2D and 3D 
culture and in an ex vivo model of pancreatic cancer. 
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7 COMMENTS ON THE METHODOLOGIES 
7.1 ETHICAL CONSIDERATIONS 
All four studies involved patient tissue (Papers I, II and IV) or isolated primary hepatocytes 
(Paper III). The ethical aspects of the use of this material has been discussed extensively in 
ethical permits relating to each project. All work was approved by the Regional Ethical 
Review Board, Stockholm. Informed consent was always retrieved from patients prior to 
inclusion in the study. 
7.2 CELL LINES 
The human hepatocellular carcinoma cell lines HEPG2, Hep3B, HUH7 and the pancreatic 
ductal adenocarcinoma cell line, PANC-1 were used. The culture of PANC-1 cells in 3D 
spheroids was facilitated by the addition of methylcellulose to the media according to 
previously published report [257]. 
7.3 EX VIVO ORGANOTYPIC CULTURE  
Small pieces of pancreatic 
adenocarcinoma surgical specimens 
were sectioned using a vibratone 
microtome into 350 µM thick sections. 
The slices were cultured for up to 96 h 
on inserts in wells, in normoxic 
conditions in the presence of 5% CO2. 
7.4 GENE EXPRESSION 
7.4.1 Quantitative PCR 
SYBR green fluorescent based dye was used for qPCR where the green fluorophore 
intercalates with each new copy of dsDNA. Gene expression was quantified by the 2-∆∆Ct 
method by normalizing to a reference gene.  
7.5 PROTEIN DETECTION 
7.5.1 Affinity purification of antibodies 
Rabbits were immunized by serial injections with antigen proteins at Agrisera. The sera was 
collected and the antibodies were precipitated by the addition of 50% ammoniumsulfate 
solution. After a centrifugation step, the supernatant was discarded and the pellet of 
antibodies was re-suspended and subjected to dialysis with PBS. Specific antibodies were 
eluted by the Affigel (BIORAD) columns with immobilized antigen protein. These antibodies 
were used for immunoblotting and immunohistochemical analysis for investigation of protein 
expression patterns.  
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7.5.2 Immunohistochemistry 
Protein expression patterns in tissue was investigated by immunohistochemical analysis. 
Paraffin-embedded tissue samples were sectioned and stained on glass with primary and 
secondary antibody. The sections were developed with diaminobenzidine (DAB) with a 
subsequent counterstain with hematoxylin. Images were taken by light microscope under 
standardized settings. Analysis of the saturation of the staining was performed by NIS 
Elements BR Software. 
7.5.3 Immunoblotting 
CELLS 
Detection of protein levels were investigated by western blot. Briefly, collected cells were 
lysed and homogenized in RIPA with added protease inhibitor cocktail. Denatured proteis 
were separated by size on an SDS Page. The proteins were blotted on polyvinylidene fluoride 
(PVDF) membrane by semi-dry transfer. Primary antibodies against target proteins were 
incubated on the membranes and detection occurred by secondary infrared fluorescent 
IRDye® antibody in an Odyssey Fc (LI-COR®) Imaging system. Quantification of the 
protein levels occurred in the Odyssey Image software (LI-COR®) by normalizing the 
fluorescence intensity of signals to the reference signal.  
TISSUE 
Protein purification from liver tissue biopsies also ocurred. A small piece of tissue, a few mg, 
was placed in a round-bottom Eppendorf tube with a 5 mm stainless steel marble. Addition of 
RIPA and protease inhibitor cocktail occurred and homogenization performed using a Tissue 
Lyser LT at 50 Hz for 2-5 minutes. Subsequent western blotting was performed as described 
above.  
7.6 VIABILITY ASSAY  
The ATP dependent luciferin enzyme converts luciferin to oxyluciferin which generates light. 
ATP production occurs in metabolically active cells, reflecting their viability. Luminescence 
based ATP assay can therefore be used to determine cytotoxic or anti-proliferative effects of 
a compound.  
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8 RESULTS AND DISCUSSION 
8.1 PAPER I 
Expression of thioredoxins and glutaredoxins in human hepatocellular carcinoma: 
correlation to cell proliferation, tumor size and metabolic syndrome 
The thioredoxin family of proteins consist of the thioredoxin (TXN) and glutaredoxin 
(GLRX) proteins. These thiol oxidoreductases are ubiquitously expressed in cells, implicated 
in various essential physiological processes. They have been seen to be overexpressed in 
neoplasms [167, 172, 173, 258-261] where they regulate processes of proliferation and 
apoptosis. We aimed to study the expression pattern of the TXN and GLRX proteins in 
hepatocellular carcinoma (HCC) in comparison to non-cancerous surrounding tissue. The 
results would then be correlated to clinical parameters.  
In order to properly investigate the protein levels in tissue, we prepared and purified 
polyclonal antibodies against isoforms of TXN and GLRX full length proteins. Human 
recombinant proteins were purified from bacteria following plasmid based overexpression 
delivery. The purified proteins were used for the immunization of rabbits were the sera was 
subsequently collected. Affinity purification of antibodies was achieved by the use of 
columns immobilized with the target protein. Antibodies were tested for specificity and cross 
reactivity with subsequent application in an immunohistochemical methodology.  
Corroborating previous reports that showed an upregulation of redox proteins in HCC [167], 
the results of this study showed an upregulation of TXN1, TXN2 and GLRX5 in cancerous 
tissue in comparison to the surrounding tissue. Primary HCC tumors most commonly arise 
due to insult on the liver tissue, exemplified by cirrhosis due to alcohol, hepatitis or non-
alcoholic fatty liver disease [235, 236]. As these conditions are implicated with an increase in 
oxidative stress, a potential increase of the basal levels of TXN and GLRX might be evident. 
For this reason, we chose to examine the expression patterns of the oxidoreductases in 
question in colorectal carcinoma (CRC) metastases of the liver as well, compared to the 
surrounding benign liver tissue. There we found an upregulation of TXN1, TXN2, GLRX1, 
GLRX3 and GLRX5.  
In HCC, TXN1 significantly correlated with cell proliferation, however, the levels of this 
isoform were lower in tumors of males, smokers and patients with high alcohol consumption 
compared to the respective contrariety group. This could be explained by the important role 
of TXN in a setting of high oxidative stress. The surrounding tissue of this patients had higher 
levels of TXN1, lowering the ratio under the investigation of the tumorous tissue. TXN2 was 
found to decrease with increasing tumor size. This is attributed to the TXN2 mediated 
attenuation of hypoxia inducible factor (HIF) [262]. Tumors acquire traits that favor 
vascularization and angiogenesis as their size increases. Reactive oxygen species (ROS) are 
involved in the mediating a HIF response to accommodate these needs [109, 110]. 
Downregulation of TXN2 levels, a thiol oxidoreductase known to mitigate the effects by 
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ROS, could therefore be a trait that favors tumor growth. All investigated isoforms were 
upregulated in CRC liver metastases except GLRX2. This isoform correlated however to 
metabolic syndrome. The advances regarding the relation of GLRX with metabolic syndrome 
has been scarce, however the TXN system has been implicated to have a protective role in 
metabolic syndrome [263]. A possible upregulation of GLRX2 expression might occur to 
circumvent the increased oxidative stress associated with metabolic disorders.  
Conclusion 
Patients with underlying liver diseases, primarily involving cirrhosis, have altered basal levels 
of TXN and GLRX proteins already in the surrounding tissue. This could result in false 
negative findings in the investigations of their expression patterns in cancerous tissue when 
compared to the adjacent surrounding tissue. The higher levels of the proteins in liver tumor 
metastases originating from CRC substantiate this to some extent. It is however important to 
note that this could be due to inherent differences between the two carcinoma types. The 
finding that TXN1 and TXN2, and GLRX5 are overexpressed in HCC warrants further study 
as the altered expression patterns could be of diagnostic value in HCC patients.  
8.2 PAPER II 
Morphological alterations and redox changes associated with hepatic warm ischemia-
reperfusion injury 
Oxidative stress in ischemia and reperfusion (IR) injury is a known cause of tissue damage 
during liver resection and transplantation. This has a direct impact on the patients’ 
postoperative morbidity and mortality [264, 265]. During ischemia, the cells are unable to 
resynthesize ATP, leading to an accumulation of the metabolites hypoxanthine and xanthine. 
In line with this, an increase in intracellular Ca2+ occurs due to impairment in ATP dependent 
Ca2+ membrane pumps. A consequence of the high Ca2+ levels is the cleavage of the enzyme 
xanthine dehydrogenase to xanthine oxidase (XO) [65, 74, 75]. Much of the inflicted damage 
occurs at reperfusion as reintroducing blood flow to the tissue allows a burst of molecular 
oxygen to the ischemic site. XO metabolizes hypoxanthine and xanthine by the use of 
oxygen, thus generating superoxide [76]. This ROS and its derivatives elicits damage when 
present in excess accounting for the IR injury [266, 267]. A distinction is made between 
warm and cold ischemia, where the former accounts for the setting during surgery where 
blood supply is limited or constrained. Cold ischemia relates mainly to transplantation and 
the cold preservation of the tissue. The aim of the study was to study the effects of warm IR 
injury on hepatic morphology at the ultrastructural level and to study changes in the 
expression of TXN and GLRX.  
Portal triad clamping is used to limit blood loss during liver surgery. It was used in an 
experimental setting to induce a controlled environment for ischemia with subsequent 
reperfusion. Liver biopsies were collected at three time points; first prior to PTC (baseline), 
20 min after PTC (post-ischemia) and 20 min after reperfusion (post-reperfusion). For the 
investigation of ultrastructural changes, electron microscopy was implemented. Detection of 
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TXN and GLRX gene expression was performed by qPCR while protein expression of the 
isoforms TXN1 and GLRX1 was studied by immunogold staining. 
The most striking finding at the ultrastructural level was a loss of liver sinusoidal endothelial 
cells (LSEC) with an apparent reduction of the microvilli of the hepatocytes at these sites. 
Surprisingly, there were more LSECs lining the sinusoidal wall after 20 minutes of 
reperfusion then seen in the ischemic tissue. Several of the cells displayed pseudopod-like 
extensions indicative towards an activation of the LSECs. Earlier reports show harmful 
effects of cold ischemia on LSECs while hepatocytes display alterations initially, before other 
cell types, in warm ischemia [268, 269]. This was not in line with the findings of our study, 
however, the duration of ischemic insult is important to take into consideration as well as the 
extent of reperfusion. Additionally, late phase effects of reperfusion were not investigated in 
this study.   
Investigation of the hepatocytes at IR revealed preserved morphology in the ischemic tissue 
with the exception of crystalline mitochondrial inclusion appearing in 7 out of 11 patients. 
This was accompanied with dilated mitochondria, both elongated and rounded. Crystalline 
inclusions in human mitochondria is found in patients with early alcohol- or non-alcohol 
related liver diseases, and aspirin toxicity [270-272]. The mechanisms behind the formation 
of these inclusion or what they consist of remains unknown in a human setting. Inclusions, 
morphologically similar to these, found in bacteria appear as a mean to protect mitochondrial 
DNA. They arise by the co-polymerisation of bacterial DNA with the stress induced protein 
Dps [273].  
Gene expression levels of TXN and GLRX isoforms and related redox proteins were not 
altered by IR in this setting. However the immunogold results were indicative of a possible 
redistribution of the TXN1 protein within the cell.  
Conclusion 
Hepatocyte morphology was preserved under the condition of 20 min of ischemia followed 
by 20 minutes of reperfusion, with the exception of dilated mitochondria with crystalline 
inclusions. The major impact or IR injury in this setting was borne by the LSEC with a 
detachment from the sinusoidal wall at ischemia. An activation or a possible reattachment 
could be seen in these cells after reperfusion. Portal triad clamping is mainly used 
intermittently with short periods of reperfusion, in such a setting the ultrastructural 
morphology of the liver hepatocytes is well preserved. 
8.3 PAPER III 
The selective induction of kynureninene aminotransferase 1 dramatically potentiates 
the effect of seleno-methylselenocysteine in hepatocellular carcinoma cells 
The selenium compound, methyl selenocysteine (MSC) shows strong potential for clinical 
use as a chemotherapeutic agent attributed to its tumoricidal effects. Its high bioavailability 
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and low risk for selenosis renders it suitable for peroral use. MSC itself is a relatively atoxic 
compound, eliciting its effects via its metabolites, mainly methylselenol and 
methylselenopyryvate (MSP). Transamination of MSC results in the formation of MSP while 
a β-elimination is required for generation of methylselenol which is highly reactive and toxic 
to cells.  
Kynurenine aminotransferases (KYAT) are cysteine S-conjugate β-lyases that possess both 
transaminase and β- lyase activity depending on the substrate and the co-factors present. They 
cleave S-C bonds and display high affinity for certain Se-C bonds as well. MSC in particular 
has been shown to be a better substrate for KYAT1 than its corresponding S-analogue. In this 
study, we aimed to increase the growth inhibitory effects of MSC by overexpressing KYAT 
enzymes. Additionally, we hypothesized that cells would be further sensitized to MSC by 
propagating the β-lyase activity of KYAT enzymes as opposed to transaminase activity. This 
in turn would generate more methylselenol and elicit more cellular toxicity.  
HCC cell lines and primary hepatocytes were transfected with a vector-based overexpression 
system. An additional means of transfection was implemented by the use of specific delivery 
system of stable mRNA of KYATs encapsulated in a particle. In order to further enhance the 
growth inhibitory effects of MSC by KYAT metabolism, we modulated the system to favor 
β-elimination over transamination. This was aided by the addition of transaminase inhibitors, 
co-factors for β-elimination propagation, and site directed mutagenesis of the vector-
delivered KYAT1 coding sequence.  
Transient overexpression of KYAT1 resulted in an increased sensitivity towards MSC. This 
was evident by both vector based transfection and delivery of stable mRNA. Modulating the 
cleavage of MSC by favoring β-elimination over transamination further sensitized the cells. 
In detail, addition of an α-keto acid significantly increased the growth inhibitory effects of 
MSC in HEPG2 and in Hep3B cells. This α-keto acid facilitates the regeneration of the co-
factor PLP, which is essential for the β-lyase activity of these enzymes. In line with these 
results, we sought out to modify and overexpress KYAT1 to elicit more β-lyase activity. Site 
directed mutagenesis was implemented generating two mutants that dramatically increased 
the growth inhibitory effects of MSC in HEPG2 cells.  
Conclusion 
Sensitivity towards MSC can be enhanced by the overexpression of the metabolizing enzyme 
KYAT1. Furthermore, modulating the enzyme activity to favor β-lyase over transaminase 
activity increased the growth inhibitory effects of MSC to an even greater extent. Modulation 
occurred by the means of transaminase inhibitors and by site directed mutagenesis, generating 
two different mutants of KYAT1 with higher affinity for the β-elimination of MSC. 
The specific RNA delivery system provides an interesting approach for a clinical setting as 
the particles can be produced to express ligands on their surface that binds to tumor specific 
antigens or receptors. Taken together, an extremely interesting approach for cancer treatment 
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would be the delivery of stable mRNA encoding our mutant KYAT1 via particles that 
directly target tumor cells.  
8.4 PAPER IV 
Prominent cytotoxicity and interactions of selenium compounds with standard 
cytostatic drugs in 2D and 3D in vitro models and in an ex vivo organotypic model using 
surgical specimens from patients with pancreatic ductal adenocarcinoma 
Existing models for the use of preclinical drug testing rely mainly on in vitro cell culture with 
immortalized cells. Limitations of monolayer cell culture of cancer cells include, among other 
things, a lack of tumor microenvironment and a loss of phenotypic traits exhibited in the 
original malignancy. These traits make results difficult to translate to a human in vivo setting. 
Developments in the field of research addressing some of the limitations gave rise to the 
formation of 3D spheroids [274, 275]. This allowed for a higher resemblance to an in vivo 
setting considering the growth of a solid tumor. Our group recently developed a novel 
approach for culturing pancreatic cancer tissue from surgical specimens in an ex vivo 
organotypic model system. Results obtained from this culture model would even better reflect 
the in vivo environment compared to cells grown in 3D spheroids. In this study, we set out to 
compare the growth inhibitory effects and resistance of selenium compounds in 2D and 3D in 
vitro culture and in an ex vivo organotypic model of pancreas.  
The human pancreatic adenocarcinoma cell line PANC-1 was used for in vitro culture. The 
addition of methylcellulose to the media facilitated the formation of 3D spheroids in non-
culture treated round bottom wells [257]. The monolayer 2D cells and the 3D spheroids were 
treated with selenium compounds for 72 h and the respective half maximal inhibitory 
concentrations (IC50) were determined. The compounds tested in vitro were sodium selenite, 
MSC, and two novel compounds, seleno-folate and seleno-aniline. The response to sodium 
selenie and MSC was also investigated in combination with the cytostatic drugs 5-
fluorouracil (5-FU) and gemcitabine. For the ex vivo culture, small cubes of surgical 
specimens were sliced by the use of a vibratone microtome into 350 µm sections. These 
sections were cultured for a total of 96 h in wells with insert in order to facilitate proper tissue 
oxygenation. They were treated with the selenium compound sodium selenite or MSC in 
combination with 5-FU and gemcitabine. At the end of culture, the sections were fixated and 
paraffin embedded for immunohistochemical analysis.  
The results revealed less sensitivity towards sodium selenite in the 3D spheroid compared to 
cells grown in monolayer culture. This was also seen for the novel compound seleno-aniline. 
The response to MSC or seleno-folate did not differ amongst the two in vitro systems. Co-
treatment of sodium selenite with the cytostatic agent 5-FU protected the cells from selenite 
mediated growth inhibition or toxicity in 2D cultured cells. Gemcitabine in combination with 
a higher level of MSC on the other hand showed increased growth inhibition. We attribute 
this to the different modes of action of the selenium compounds. The efficacy of sodium 
selenite and MSC alone and in combination with 5-FU and gemcitabine was also studied in 
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an ex vivo organotypic model of pancreatic cancer. The cytostatic agents administered as 
single agents didn’t elicit any inhibitory effects on the tissue. Sodium selenite in combination 
with the 5-FU showed higher metabolic activity, a similar pattern as seen in the PANC-1 
cells. The treatment with MSC however, elicited a strong response in the tissue, reducing the 
metabolic activity of the residing cells.  
Conclusion 
Cells grown in spheroids show less sensitivity towards some compounds when compared to 
monolayer culture. This highlights once again the importance in choosing adequate model 
systems for investigation of drug efficacy. The use of an ex vivo organotypic model for drug 
screening opens up possibilities for novel approaches of drug screening systems that mimic 
an in vivo setting. This is outmost of importance in the development of new tools for 
translational research. 
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9 CONCLUSION AND FUTURE PERSPECTIVES 
Oxidative stress arises due to an excessive generation of reactive oxygen species (ROS) or to 
impairment or dysfunction in the antioxidant capabilities of a cell. This in turn is implicated 
in several pathological disorders, including neurodegenerative disorders, cardiovascular 
disease, ischemia and reperfusion (IR) injury and cancer. The investigation of this thesis 
mainly addresses two parts, revolving around the redox status of the cell and tissue. 
I. Expression patterns of thioredoxin (TXN) and glutaredoxin (GLRX) isoforms in two 
settings associated with oxidative stress, hepatocellular carcinoma (HCC) and IR 
injury in the liver.  
II. Inducing additional oxidative stress in cancer cells by the means of redox active 
selenium compounds, mainly sodium selenite and methylselenocysteine (MSC) for 
chemotherapeutic purposes. 
9.1 PART I 
The oxidoreductases TXN and GLRX have been seen to be overexpressed in many cancerous 
tissues compared to healthy tissue. Paper I investigated a presumed upregulation of these 
proteins in relation to various clinical parameters. As expected, higher levels of TXN1 was 
found in HCC tissue compared to surrounding tissue. Other isoforms with elevated levels 
were TXN2 and GLRX5. Many of the patients included in the study presented with 
underlying liver disease. The surrounding non-cancerous tissue could have inherent increased 
levels of oxidoreductases, adapted to circumvent oxidative stress of chronic disease. 
Expression pattern of TXN and GLRX isoforms in colorectal carcinoma (CRC) liver 
metastases were investigated as well and compared to the surrounding healthy tissue. All 
isoforms but one, GLRX2, was found to be upregulated in the tumor cells. Further studies are 
warranted to study the role of these proteins in the tumor progression and growth. Such 
results could shed a light on the application of targeted therapy against the TXN and GLRX 
isoforms in liver tumors. Their potential implications in a clinical setting as prognostic and 
predictive markers for HCC merits investigation. 
At reperfusion, there is a burst of molecular oxygen reintroduced to the ischemic tissue. This 
leads to a high generation of reactive oxygen species. An experimental setting using portal 
triad clamping in liver was used as a model system in Paper II for a controlled setting of IR 
injury. During the short time period of reperfusion, however, ultrastructural changes were 
seen by transmission electron micrographs. The results exhibited a loss or detachment of liver 
sinusoidal endothelial cells at ischemia with a possible activation and reattachment after 
reperfusion. This is indicative of the effects being reversible to some extent when the IR 
insult is limited by time. Hepatocyte morphology on the other hand remained primarily intact 
with the exception of mitochondrial crystalline inclusions. These structures could be an 
evolutionary preserved event in response to a stress response such as IR, given the role these 
inclusions hold in bacteria. Mitochondria has long been known to be subjected to DNA 
damage due to oxidative stress and initially was thought to lack any DNA repair processes 
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[276]. This merits further studies for elucidating the mechanism behind the formation of 
crystalline inclusions in relation to oxidative stress and to shed light on a potential DNA 
protective mechanism,  
9.2 PART II  
The increased metabolism in tumor cells generates a high level of ROS which in turn also 
favors malignancy. The increased basal level renders the cell vulnerable to subtle changes in 
the oxidative state. Initiating ROS-production will drive the tumor cells over the threshold 
resulting in cell death. Redox active selenium compounds elicit a multi-target response in 
cells, with their tumoricidal effects being attributed to downstream generation of ROS and 
cell death activation.  
MSC is a potent prodrug with high potential for the use in cancer therapy. Its high 
bioavailability is attributed to favorable pharmacokinetics with low risk for selenosis. For the 
compound to exert its anti-neoplastic effects it needs to be cleaved to the reactive metabolites 
methylselenol or methylselenopyruvate. This is achieved by β-elimination and transamination 
respectively. A class of enzymes known to cleave MSC to its respective metabolites is the 
kynurenine aminotransferases (KYATs). KYATs possess both transaminase and β-lyase 
activity.  
In Paper III, modulation of KYATs in liver cells was implemented to increase their 
sensitivity towards the inhibitory effects of MSC. This was first achieved by vector based 
overexpression of KYAT1.  This, however, is not feasible for the use in vivo, therefore an 
additional delivery system was utilized, involving encapsulated stable mRNA of KYAT1 and 
KYAT3. Successful transfection by this system provides promising potential for increasing 
the levels of metabolizing enzymes in a cell, thus potentiating effects of administered 
prodrugs. To further enhance sensitivity towards MSC treatment, the overexpressed enzymes 
were modified by site directed mutagenesis to favor the formation of methylselenol via β-
elimination. This study displayed enhanced growth inhibitory effects by MSC in such a 
setting. Taking these results together it would be highly interesting to create stable mRNA of 
mutant KYAT1 delivered to cells by targeting specific features on tumor cells. This would in 
turn enhance the efficacy of peroral administered MSC while reducing the side effects in 
benign cells.  
Cancerous tissue involves a multi-faceted environment including different types of cells and 
stimuli. Culturing precision cut slices maintains all constituents of the tissue, eliciting a 
response that better reflects the in vivo situation. Recently, our group developed a novel ex 
vivo organotypic model of pancreatic carcinoma slices from surgical specimen. Paper IV 
examined the effects of selenium compounds as single agents and in combination with the 
cytostatic drugs 5-fluorouracil (5-FU) and gemcitabine in different drug screening systems, 
comparing in vitro 2D and 3D models with the ex vivo organotypic model. Resistance in cells 
grow in 3D spheroids compared to 2D monolayer culture depended on the drug administered. 
MSC in particular effected the pancreatic tissue slice the most, with a potentiating effect 
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when combined with gemcitabine and 5-FU. These results provide insight on the use of MSC 
both as a single agent and in combination with cytostatic agents. The advantageous aspects 
offered by co-treatment include a low required dose of the chemotherapeutic agent, thus 
reducing potential side effects. Another benefit is the multi-targeted approach elicited by 
using different compounds which in turn would lower the risk for acquired drug resistance.  
Implementation of the ex vivo culture in a clinical setting for the development of personalized 
therapy merits further investigation. Pancreatic adenocarcinoma patients generally receive a 
combination of 5-FU or gemcitabine-based therapy in the clinic. The response towards these 
two cytostatic agents is investigated in the ex vivo slices of surgical specimen retrieved from 
these patients as well. A first approach could be to review the patient records retrospectively 
in order to correlate the response in vivo after chemotherapeutic treatment, with the results 
seen in their respective ex vivo culture. 
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